CD8A and neoplasm: In addition, paclitaxel promotes the development of tumor-infiltrating lymphocytes (TIL)20,21, while the response to anti-PD-L1 therapy correlates with pre-existing tumor immunity like CD8+ infiltrating cells and TH1-type CD4+ activated lymphocytes22.